Bio Sequence

Toripalimab: FDA Greenlights First made-in-China PD-1 and Its Evolving Competitive Landscape

31 October 2023
3 min read

With the FDA's approval of toripalimab monoclonal antibody for use in all treatment regimens for recurrent or metastatic nasopharyngeal carcinoma (NPC), the first Chinese PD-1 is set to enter the U.S. market.

Junshi Biosciences became the first Chinese manufacturer to receive approval for a checkpoint inhibitor in China in 2018 and is the drug’s original developer. However, Coherus BioSciences pre-paid $150 million at the start of 2021 to secure the rights in the U.S. and Canada. The antibody is marketed as Tuoyi in China and under the brand name Loqtorzi in the U.S., with a planned launch in the first quarter of 2024.

A Panoramic View of Toripalimab’s Top 10 Patent Assignees

According to the Patsnap Bio Sequence Database, the top 10 applicants for the toripalimab patent are Shanghai Junshi Biosciences with 52 applications, Cugene with 30 applications, and Guangzhou Zhiyi Biotech with 16 applications. For more applicants, please refer to the image below.

Source, Patsnap Bio

Evolution of the Layout of Top 10 Patent Assignees over the years, the Competitive landscape over time

Exploring the changes occurring within the application structure amongst toripalimab's top 10 patent assignees over time delivers insights into the competitive landscape's evolution.

Source, Patsnap Bio

How Can You Acquire Comprehensive Information on Toripalimab Sequence Patents for Free?

Firstly, establish a free account with Patsnap Bio Sequence Database. Proceed to the homepage's "standard search," and enter the toripalimab sequence or directly input the drug name, toripalimab, in the "Drug/Gene index. This single action will unravel extensive details of toripalimab's sequence, patent, literature, data from diversified sources, and a visually competitive landscape of patents.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The left panel's search result details page is equipped with an exhaustive range of filters, enabling you to pinpoint specific data accurately, thereby boosting your search experience and overall efficiency. Clicking on each data point will unfold a rich and detailed data set and a host of advantageous and practical tools to support your research process.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

It is important to note that Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated, illuminating structural modifications to provide the most accurate sequence data and boost sequence retrieval efficiency.

Free registration is available for the Bio biological sequence database: https://bio.patsnap.com. Act now to expedite your sequence search tasks.

Unleashing the Power of Doxycycline Calcium: A Comprehensive Review on R&D Breakthroughs
Drug Insights
4 min read
Unleashing the Power of Doxycycline Calcium: A Comprehensive Review on R&D Breakthroughs
2 November 2023
This article summarized the latest R&D progress of Doxycycline Calcium, the Mechanism of Action for Doxycycline Calcium, and the drug target R&D trends for Doxycycline Calcium.
Read →
Ciltacabtagene autoleucel Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Ciltacabtagene autoleucel Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
2 November 2023
This article summarized the latest R&D progress of Ciltacabtagene autoleucel, the Mechanism of Action for Ciltacabtagene autoleucel, and the drug target R&D trends for Ciltacabtagene autoleucel.
Read →
 Unleashing the Power of Clocortolone Pivalate: A Comprehensive Review on R&D Breakthroughs
Drug Insights
3 min read
Unleashing the Power of Clocortolone Pivalate: A Comprehensive Review on R&D Breakthroughs
2 November 2023
This article summarized the latest R&D progress of Clocortolone Pivalate, the Mechanism of Action for Clocortolone Pivalate, and the drug target R&D trends for Clocortolone Pivalate.
Read →
A Comprehensive Review of Clofarabine's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Clofarabine's R&D Innovations and Drug Target Mechanism
2 November 2023
This article summarized the latest R&D progress of Clofarabine, the Mechanism of Action for Clofarabine, and the drug target R&D trends for Clofarabine.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.